Dataset Information

High-throughput mass spectrometry and bioinformatics analysis of breast cancer proteomic data

ABSTRACT: The project contains raw and result files from a comparative proteomic analysis of malignant [primary breast tumor (PT) and axillary metastatic lymph nodes (LN)] and non-tumor [contralateral (NCT) and adjacent breast (ANT)] tissues of patients diagnosed with invasive ductal carcinoma. A label-free mass spectrometry was conducted using nano-liquid chromatography coupled to electrospray ionization–mass spectrometry (LC-ESI-MS/MS) followed by functional annotation to reveal differentially expressed proteins and their predicted impacts on pathways and cellular functions in breast cancer. A total of 462 proteins was observed as differentially expressed (DEPs) among the groups of samples analyzed. Ingenuity Pathway Analysis software version 2.3 (QIAGEN Inc.) was employed to identify the most relevant signaling and metabolic pathways, diseases, biological functions and interaction networks affected by the deregulated proteins. Upstream regulator and biomarker analyses were also performed by IPA’s tools. Altogether, our findings revealed differential proteomic profiles that affected the associated and interconnected cancer signaling processes.

INSTRUMENT(S): LTQ Orbitrap XL ETD

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Breast, Lymph Node, Breast Cancer Cell

DISEASE(S): Breast Cancer

SUBMITTER: Michel Batista

LAB HEAD: Enilze Maria de Souza Fonseca Ribeiro

PROVIDER: PXD012431 | Pride | 2019-07-15

REPOSITORIES: Pride

ACCESS DATA

Publications

High-throughput mass spectrometry and bioinformatics analysis of breast cancer proteomic data.

Gomig Talita Helen Bombardelli THB Cavalli Iglenir João IJ Souza Ricardo Lehtonen Rodrigues de RLR Lucena Aline Castro Rodrigues ACR Batista Michel M Machado Kelly Cavalcanti KC Marchini Fabricio Klerynton FK Marchi Fabio Albuquerque FA Lima Rubens Silveira RS Urban Cícero de Andrade CA Cavalli Luciane Regina LR Ribeiro Enilze Maria de Souza Fonseca EMSF

Data in brief 20190610

Data present here describe a comparative proteomic analysis among the malignant [primary breast tumor (PT) and axillary metastatic lymph nodes (LN)], and the non-tumor [contralateral (NCT) and adjacent (ANT)] breast tissues. Protein identification and quantification were performed through label-free mass spectrometry using a nano-liquid chromatography coupled to an electrospray ionization-mass spectrometry (nLC-ESI-MS/MS). The mass spectrometry proteomic data have been deposited to the ProteomeX ...[more]

PMID: 31294064

Similar Datasets

Project description:Purpose The analysis of breast cancer residual tumors after neoadjuvant chemotherapy (nCT) may be useful for identifying new biomarkers. MicroRNAs are known to be involved in oncogenic pathways and treatment resistance of breast cancer. Our aim was to determine the role of miR-18a, a member of the miR-17-92a cluster, in breast cancer behavior and outcome after nCT. Methods Pre- and post-nCT tumor miR-18a expression was retrospectively assessed by qRT-PCR in 121 patients treated with nCT and was correlated with survival outcomes and with clinical and pathological characteristics. Breast cancer-derived MCF-7 and MDA-MB-231 cell lines were transfected with miR-18a and anti-miR-18a to evaluate the biological effects of this molecule. In addition, whole-transcriptome expression analysis was performed. Results High miR-18a expression in post-nCT residual tumors was found to be associated with a significantly worse overall survival [hazard ratio (HR): 2.80, 95% confidence interval (CI): 1.01–7.76] and a strong trend towards a poorer disease-free survival (HR: 2.44, 95% CI: 0.99–5.02) compared to low miR-18a expressing post-nCT residual tumors. Clinical and experimental data were found to be in conformity with the proliferative effects of miR-18a, which showed a significant correlation with Ki67 and MYBL2 expression, both in pre- and post-nCT tumors and in public databases. In vitro analysis of the role of miR-18a in breast cancer-derived cell lines showed that a high expression of miR-18a was associated with a low expression of the estrogen receptor (ER), a decreased sensitivity to tamoxifen and an enrichment in luminal B and endocrine resistance gene expression signatures. Conclusions From our data we conclude that post-nCT miR-18a expression in breast cancer serves as a negative prognostic marker, especially in luminal tumors. Clinical, in vitro and in silico data support the role of miR-18a in breast cancer cell proliferation and endocrine resistance and suggest its potential utility as a biomarker for additional adjuvant treatment in patients without a pathologic complete response to neoadjuvant therapy.

Dataset Information

High-throughput mass spectrometry and bioinformatics analysis of breast cancer proteomic data

Publications

High-throughput mass spectrometry and bioinformatics analysis of breast cancer proteomic data.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure